MyMD Pharmaceuticals Inc. announced that a human cell research study of lead clinical compound MYMD-1 found the drug to be effective in suppressing the cytokine storm, a major cause of severity and death in COVID-19 patients.
Akers Biosciences and MyMD Pharmaceuticals reported that a new study showed rising temperatures during spring and summer months are associated with slower rates of Covid-19 transmission, which is consistent with the seasonal respiratory virus’ behaviour.